Diabetes Mellitus Type 2 in Obese, Inflammation, Metabolic Disease, Glucose Metabolism Disorders (Including Diabetes Mellitus)
Conditions
Keywords
anakinra, cephalic phase of insulin secretion
Brief summary
A prospective, randomized, mixed double- and single-blinded, placebo-controlled, cross-over clinical trial to test whether acute treatment with an IL-1 receptor antagonist impacts insulin secretion over time during the cephalic phase, defined as the first 10 minutes after the first sensorial contact to food, in healthy individuals in healthy humans (Group 1) and in obese patients with type 2 diabetes (Group 2).
Detailed description
The role of the immune system in metabolism has been extensively investigated in pancreatic islets and insulin sensitive tissues. However little attention has been given to a potential role of the innate immune system in the cephalic phase of insulin secretion. In humans, the cephalic phase of insulin secretion appear reduced in obesity and in patients with type 2 diabetes. In this prospective, randomized, mixed double- and single-blinded, placebo-controlled, cross-over clinical trial we aim to test whether acute treatment with an IL-1 receptor antagonist impacts insulin secretion over time during the cephalic phase, defined as the first 10 minutes after the first sensorial contact to food, in healthy individuals in healthy humans (Group 1) and in obese patients with type 2 diabetes (Group 2). Group 1: After screening, subjects will be randomized to two crossover visits with a washout period of at least 4 days in-between visits and at most two weeks: A) subcutaneous saline injection 3h before an oral standardized meal, B) subcutaneous injection of 100 mg of the IL-1 receptor antagonist anakinra 3h before an oral standardized meal. Treatments will be placebo controlled, crossover, double blinded. The study will be performed in a population of healthy individuals. Group 2: Same as for Group 1 with the following addition: after the second study day, participant in group 2 will be trained to self-inject the medication for 6 days. On the 7th day, an oral standardized meal test will be performed. Healthy subjects from group 1 will be matched for sex and age to the diabetic cohort from group 2.
Interventions
Subcutaneous injection of 100 mg/ 0.67 ml of Kineret or placebo
Sponsors
University Hospital, Basel, Switzerland
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Masking description
Randomized, double-blinded and open-label, placebo-controlled, partly cross-over clinical trial
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
Main inclusion criteria: * Age ≥ 18 years and ≤ 70 years at screening * Male or female of non-child-bearing potential (meaning for women: not currently pregnant, post-menopausal female or using condoms and either intrauterine devices or 3-monthly contraceptive injection or birth-control pill.) Healthy subjects: * No apparent disease requiring medication * BMI \< 25 kg/ m2 * C-reactive protein ≤ 2 mg/L Obese diabetic type 2 subjects: * Type 2 diabetes * HbA1c 7.0 -10.0% * BMI ≥ 30.0 kg/m2 * C-reactive protein ≥ 2 mg/L
Exclusion criteria
Subjects will be excluded from the study if they meet any of the following criteria: * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * Aversion or allergy to paracetamol or any component of the meal. * Known history of allergy or hypersensitivity to any component of the investigational product formulations * Concomitant treatment with GLP-1 agonists, DPP-4 inhibitors, insulin or insulin derivative * Change in diabetes medication within the last 30 days * Any biologic drugs targeting the immune system * Fever, or other signs of infection requiring antibiotics within 3 weeks prior to screening, history of recurrent infection, immunodeficiency, known HIV or tuberculosis infection, active foot ulcer * Participation in another study with investigational drug within 30 days prior to Screening and during the present study * eGFR \< 30 mL/min/1.73m2 per MDRD formula or kidney transplant (regardless of renal function) * Known active or recurrent hepatic disorder (including cirrhosis, hepatitis B and hepatitis C, or confirmed ALAT/ASAT levels \> 3 times ULN or total bilirubin \> 2 times ULN), * Haemoglobin \<10.0 g/dL, white blood cell \<3.0 x 103/mm3, platelet count \<125 x 103/mm3 * Atrial fibrillation and/or a pacemaker
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in insulin concentration in blood during the cephalic phase of insulin secretion in healthy individuals | 10 minutes | Insulin concentration in blood at 0, 3,6 and 10 minutes after ingestion of a standardized meal in healthy individuals. |
| Change in insulin concentration in blood during the cephalic phase of insulin secretion in obese patients with type 2 diabetes | 10 minutes | Insulin concentration in blood at 0, 3, 6 and 10 minutes after ingestion of a standardized meal in healthy individuals in obese patients with type 2 diabetes. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of glucose | 6 hours | Plasma level of glucose before and after a standardized meal after acute treatment or repeated treatment with anakinra or placebo. Repeated Treatment applies only to anakinra and to Group 2. |
| Change of glucagon | 6 hours | Plasma level of glucagon before and after a standardized meal after acute treatment or repeated treatment with anakinra or placebo. Repeated Treatment applies only to anakinra and to Group 2. |
| Change of GLP-1 | 6 hours | Plasma level of GLP-1 before and after a standardized meal after acute treatment or repeated treatment with anakinra or placebo. Repeated Treatment applies only to anakinra and to Group 2. |
| Change of pancreatic polypeptide | 6 hours | Plasma level of pancreatic polypeptide before and after a standardized meal after acute treatment or repeated treatment with anakinra or placebo. Repeated Treatment applies only to anakinra and to Group 2. |
| Change of IL-1β | 6 hours | Plasma level of IL-1β before and after a standardized meal after acute treatment or repeated treatment with anakinra or placebo. Repeated Treatment applies only to anakinra and to Group 2. |
| Change of C-peptide | 6 hours | Plasma level of c-peptide before and after a standardized meal after acute treatment or repeated treatment with anakinra or placebo. Repeated Treatment applies only to anakinra and to Group 2. |
| Change of IL-1Ra | 6 hours | Plasma level of IL-1Ra before and after a meal through nasogastric tube or with anakinra or placebo after a standardized meal. |
| Change of TNFa | 6 hours | Plasma level of TNFa before and after a standardized meal after acute treatment or repeated treatment with anakinra or placebo. Repeated Treatment applies only to anakinra and to Group 2. |
| change in hunger | 6 hours | Visual analogue scale (VAS) for hunger (from minimum value = not hungry at all to maximum value = extremely hungry) before and after a standardized meal after acute treatment or repeated treatment with anakinra or placebo. Repeated Treatment applies only to anakinra and to Group 2. |
| Change in autonomic function | 6 hours | Change in heart-rate variability during a continuous ECG as indirect measure of measure of the autonomic function before and after a standardized meal after acute treatment or repeated treatment with anakinra or placebo. Repeated Treatment applies only to anakinra and to Group 2. |
| Change of IL-6 | 6 hours | Plasma level of IL-6 before and after a standardized meal after acute treatment or repeated treatment with anakinra or placebo. Repeated Treatment applies only to anakinra and to Group 2. |
| Change of insulin | 6 hours | Plasma level of insulin before and after a standardized meal after acute treatment or repeated treatment with anakinra or placebo. Repeated Treatment applies only to anakinra and to Group 2. |
Countries
Switzerland
Outcome results
None listed